Medifocus Inc. develops and commercializes minimally invasive treatment systems for malignant and benign tumors, specifically in breast and prostate cancers. The Adaptive Phased Array (APA)-1000 precisely focuses and controls microwave energy to shrink breast cancer tumors without side-effects. For prostate cancer, the Prolieve® System is based on endo-thermotherapy that dilates the prostatic urethra and heats the prostate.
Cheung says his vision is to be able to use focus heat treatment to target malignant and benign tumors in order to restore patients to full health.
“The reason is that focus heat treatment does not have side effects. It does not have cumulative toxicity, light radiation, or chemotherapy. By working with MIT Lincoln Laboratory, we have an adaptive phased array focus heat technology that will allow us to focus heat only where the tumor is and spare the normal tissue.”
He says that the vision is to be able to make multiple systems available for various parts of the body in order to provide innovative treatment to restore health to all cancer patients.
Before Medifocus Inc., Cheung founded Celsion Corporation in the United States and was a professor at the University of Maryland. He is a well-known microwave expert and has raised significant capital for Celsion. He received a PhD in Electrical Engineering from the University of Maryland.